Pyruvate Kinase Inhibitors
2 drugsAbout Pyruvate Kinase
Pyruvate Kinase (PK) is an enzyme that regulates the final step of glycolysis, converting glucose to pyruvate and producing ATP. It plays a crucial role in cellular energy metabolism.
Pyruvate Kinase is a drug target due to its role in energy production, but there is currently no genetic evidence linking it to specific diseases.
Two FDA-approved small molecule drugs, PYRUKYND and AQVESME, target Pyruvate Kinase. Both drugs are marketed by Agios Pharmaceuticals for 'other' therapeutic areas.
Top Pyruvate Kinase Drugs
Agios Pharmaceuticals is the only company with approved drugs targeting Pyruvate Kinase.
High market concentration indicates potential entry barriers; consider partnership or novel approach.
Pyruvate Kinase Drug Modality Landscape
Modalities
Routes of Administration
Pyruvate Kinase is amenable to small molecule drugs, with oral options available for convenient dosing.
Explore alternative modalities like biologics to differentiate from existing therapies.
Pyruvate Kinase Clinical Trials 20 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Pyruvate Kinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 7 | 6 | 0 | 1 | 100% |
| Phase 2 | 4 | 0 | 1 | 3 | 0% |
| Phase 3 | 8 | 1 | 0 | 7 | 100% |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pyruvate Kinase Drug Approval Timeline (2022 - 2022)
The first drug targeting Pyruvate Kinase was approved in 2022, with the most recent approval also in 2022.
Recent approvals suggest renewed interest, but rapid succession may indicate market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Pyruvate Kinase. A trial counts if an approved drug acting on Pyruvate Kinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.